Mercedes M. Condy

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i> -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson, William D. Tap, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2013 · 396 citations · Full text

Medicine, Oncology, Pharmacology +16

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler et al. · JAMA Oncology · 2020 · 205 citations · Full text

Life Sciences, Immunology, Oncology +17

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Gary K. Schwartz, William D. Tap, Li-Xuan Qin et al. · The Lancet Oncology · 2013 · 187 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Mrinal M. Gounder, Alona Zer, William D. Tap et al. · Journal of Clinical Oncology · 2016 · 165 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

Evan Rosenbaum, Ciara M. Kelly, Sandra P. D’Angelo et al. · The Oncologist · 2019 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17